24/7 crisis support · US
Immediate crisis counseling by phone or text anywhere in the United States.
FreeResources
Everything else worth knowing about
Support lines, organizations, research, books, events, and official registries, reviewed by us, run by other people.
Need help right now?
Call or text 988 for the US Suicide & Crisis Lifeline, or 62-FIRESIDE for free peer support during a psychedelic experience. In immediate danger, call 911.
17 resources
Support lines
Talk to someone nowPeer support line · 62-FIRESIDE
Free, confidential peer support by phone or text during and after a psychedelic experience.
FreeClinician directory
Directory of licensed therapists and prescribers offering preparation and integration care.
Organizations
Non-profits and harm reductionHarm reduction
Drug checking kits, dosing information, and harm reduction education for events and personal use.
FreeResearch funder
Funds and designs psilocybin studies at major academic medical centers.
Non-profit · founded 1986
The organization behind most MDMA-assisted therapy research, plus policy and education work.
Research
Studies, trials, and archivesFederal registry
Search active psilocybin, MDMA, and ketamine trials by condition and location, the only lawful access in most states.
FreeReference archive
Long-running archive of substance pharmacology, interactions, and firsthand experience reports.
FreeAcademic center
Published studies on psilocybin for depression, anxiety, and smoking cessation, plus participant recruitment.
Books
Worth reading firstFrançoise Bourzat · 2019
Ethics, preparation, and integration from a practitioner trained in indigenous lineages.
Michael Pollan · 2018
The mainstream introduction to modern psychedelic science, history, and the people driving it.
James Fadiman · 2011
A practical manual on preparation, session structure, and the role of a guide.
Events
Conferences and gatheringsNew York, NY · October 2026
Long-running annual forum on psychedelic research, policy, and culture.
Denver, CO · June 2026
The largest psychedelic conference in the world, covering research, policy, and practice.
Tools & registries
Registries and referencesState regulator
Licensing authority and public license lookup for healing centers and facilitators.
FreeState regulator
Official licensing rules, client bill of rights, and the public registry of licensed centers and facilitators.
FreeInteraction reference
Widely used reference for dangerous combinations. Always confirm with a prescriber before changing anything.
FreeKnow something we missed?
Send us a resource with its public source and we'll review it for inclusion.
Suggest a resourceGuides
Plain-language PsiloAtlas guides, each with its sources listed.
- 5-MeO-DMT: what to knowWhat 5-MeO-DMT is, what early research shows, and its legal status in the US.
- Ayahuasca and DMT: what to knowWhat ayahuasca and DMT are, what research shows, the risks, and where they stand legally in the US and abroad.
- How to choose a facilitatorCredentials to verify, questions to ask, and the red flags that should end a consultation.
- Ibogaine: what it is, the risks, and the lawIbogaine is a long-acting psychedelic from the iboga shrub, studied for opioid use disorder and traumatic brain injury. It carries real heart risks and is illegal under US federal law.
- Is this right for me? A screening primerThe health history, medications, and life circumstances that make psychedelic sessions unsafe or ill-timed.
- Ketamine treatment: what's approved and what isn'tKetamine is legal to prescribe in the US. A nasal form, esketamine (Spravato), is FDA-approved for treatment-resistant depression; IV ketamine for depression is legal but off-label.
- MDMA-assisted therapy: research and legal statusMDMA is being studied as an aid to therapy for PTSD. The FDA declined to approve it in 2024, and it remains illegal under US federal law outside approved research.
- Psilocybin and the default mode networkWhat brain-imaging studies suggest about psilocybin and the default mode network, and why the mechanism remains unsettled.
- Psychedelics 101: the honest starting pointWhat these substances are, what they actually do, and the vocabulary you'll see everywhere else on this site.
- Set, setting, and safety basicsThe foundations of harm reduction: mindset, environment, screening, and who should not participate.
- The art of integrationPractical ways to reflect on an experience and consider what, if anything, to carry into daily life.
Official forms and law texts
Government forms, rules and statutes. We link to the official site rather than hosting copies, so you always get the current version.
- Oregon Psilocybin Services forms Oregon Health Authority, Official forms used by licensed Oregon service centers and facilitators.
- Oregon Revised Statutes, Chapter 475A (psilocybin) Oregon State Legislature, The full text of Oregon's psilocybin services law.
- Colorado Natural Medicine Program Colorado Department of Regulatory Agencies, Licensing rules and applications for Colorado facilitators.
Research papers
Peer-reviewed studies cited across PsiloAtlas.
- Bogenschutz et al. (2022) Psilocybin-assisted psychotherapy vs placebo for alcohol use disorderJAMA Psychiatry
- Carhart-Harris et al. (2021) Trial of psilocybin versus escitalopram for depressionNew England Journal of Medicine
- Davis et al. (2018) The epidemiology of 5-MeO-DMT use: benefits, consequences, patterns of useJournal of Psychopharmacology
- Davis et al. (2021) Effects of psilocybin-assisted therapy on major depressive disorderJAMA Psychiatry
- Feifel et al. (2026) Phase 2b randomized trial of intranasal mebufotenin (BPL-003) in treatment-resistant depressionJAMA
- Goodwin et al. (2022) Single-dose psilocybin for a treatment-resistant episode of major depressionNew England Journal of Medicine
- Griffiths et al. (2016) Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancerJournal of Psychopharmacology
- Human hallucinogen research: guidelines for safety (Johnson, Richards & Griffiths, 2008)Journal of Psychopharmacology
- Johnson et al. (2014) Pilot study of psilocybin in the treatment of tobacco addictionJournal of Psychopharmacology
- Magnesium–ibogaine therapy in veterans with traumatic brain injuries (Cherian et al., 2024)Nature Medicine
- Mitchell et al. (2021) MDMA-assisted therapy for severe PTSDNature Medicine
- Mitchell et al. (2023) MDMA-assisted therapy for moderate to severe PTSD: a phase 3 trialNature Medicine
- Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin (Carhart-Harris et al., 2012)PNAS
- Ot'alora G et al. (2018) MDMA-assisted psychotherapy for chronic PTSD: a randomized phase 2 trialJournal of Psychopharmacology
- Psychedelic harm reduction and integration: a transtheoretical model for clinical practice (Gorman et al., 2021)Frontiers in Psychology
- Raison et al. (2023) Single-dose psilocybin treatment for major depressive disorderJAMA
- Reckweg et al. (2023) Phase 1/2 trial of vaporized 5-MeO-DMT (GH001) in treatment-resistant depressionFrontiers in Psychiatry
- Ross et al. (2016) Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancerJournal of Psychopharmacology
State-by-state legal timeline
When each law or program took effect, newest first. Open any entry for the full summary and sources.
- Aug 1, 2026LouisianaState psychedelic-assisted therapy initiative
- Jul 1, 2026GeorgiaClinic licensing framework enacted for FDA-approved drugs
- Jul 1, 2026MississippiState-backed ibogaine clinical trials
- May 22, 2026TennesseeState ibogaine clinical trial program
- Apr 14, 2026KentuckyState ibogaine research fund; no legal access
- Jan 20, 2026New JerseyHospital psilocybin pilot program
- Jan 1, 2026Czech RepublicMedical psilocybin framework effective in 2026
- Sep 26, 2025ArizonaFDA-approved psilocybin could be prescribed once rescheduled
- Jun 20, 2025New MexicoMedical program forming
- Jun 11, 2025TexasState-funded ibogaine trials; no legal access